martedì, 5 maggio 2026

Notizie Newsletter

How the ASCO Breakthrough Global Summit Is Bringing Together Innovators to Transform Cancer Care

July 25, 2019 - Earlier this year, ASCO announced plans for its first-ever international meeting, ASCO Breakthrough: A Global Summit for Oncology Innovators, which will be held October 11–13, 2019, in Bangkok, Thailand. The meeting is a joint effort by ASCO and the ...
Leggi tutto

FDA launches its first youth e-cigarette prevention TV ads, plans new educational resources as agency approaches one-year anniversary of public education campaign

July 22, 2019 - Today, the U.S. Food and Drug Administration is announcing the launch of its first e-cigarette prevention TV ads educating kids about the dangers of e-cigarette use. The FDA also plans to provide new posters for high schools and educational materials for ...
Leggi tutto

Searching for Novel Agents to Augment Atezolizumab Approval in Small Cell Lung Cancer

July 22, 2019 - Despite the integration of frontline immunotherapy into routine practice for patients with extensive-stage small cell lung cancer (SCLC), researchers are still searching for agents with a high clinical impact that do more than fill a space of unmet need, ...
Leggi tutto

FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety

July 23, 2019 - Today, the U.S. Food and Drug Administration announced that it has issued a warning letter to Curaleaf Inc., of Wakefield, Massachusetts, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products ...
Leggi tutto

FDA Grants Breakthrough Designation to Frontline Pembrolizumab/Lenvatinib for HCC

July 23, 2019 - The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab and lenvatinib for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma (HCC) that is not amenable to locoregional therapy. The ...
Leggi tutto

FDA Approves Rituximab Biosimilar for CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

July 23, 2019 - The FDA has approved PF-05280586 (rituximab-pvvr), a biosimilar for rituximab, for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy, or for patients with CD20-positive chronic ...
Leggi tutto

FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market

July 24, 2019 - The U.S. Food and Drug Administration today took significant action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by requesting that Allergan, the manufacturer of a specific type of textured implant, recall specific ...
Leggi tutto

CAR T-Cell Therapy MB-102 Granted FDA Orphan Drug Designation for AML

July 24, 2019 - The CAR T-Cell therapy MB-102 has been granted an Orphan Drug Designation by the FDA, according to Mustang Bio, Inc, the manufacturer of the investigational treatment. MB-102, which targets CD123, previously received Orphan Drug status for the treatment of ...
Leggi tutto

FDA Grants Priority Review to Tazemetostat for Epithelioid Sarcoma

July 25, 2019 - The FDA has granted a priority review to a new drug application (NDA) for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery, according to Epizyme, the manufacturer of the EZH2 ...
Leggi tutto

Paediatric Committee elects Koenraad Norga as its new chair

July 24 2019 - At its July 2019 meeting, EMA’s paediatric committee (PDCO) elected Koenraad Norga from Belgium as its new chair, for a three-year mandate starting in September. Professor Norga will replace Dr Dirk Mentzer who is retiring as PDCO Chair, having served ...
Leggi tutto